CAR-T Cell Therapy Market by Product Type (Autologous CAR-T, Allogeneic CAR-T, In-Vivo CAR-T), by Target Antigen (CD19-Targeted, BCMA-Targeted, CD22-Targeted, Others), by Application (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Solid Tumors, Others), by End User (Hospitals & Cancer Centers, Specialty Treatment Centers, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, October 2026 — Vectomat Insights has published a new report titled ‘CAR-T Cell Therapy Market by Product Type, Target Antigen, Application, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global CAR-T Cell Therapy market was valued at USD 4,372.8 Mn in 2025 and is projected to reach USD 23,915.3 Mn by 2035, growing at a CAGR of 18.52% during the forecast period 2026–2035, according to Vectomat Insights.
Autologous products still bring in 68.0% of 2025 revenue, led by Carvykti, Yescarta and Breyanzi, but the money is moving toward off-the-shelf formats: AbbVie, AstraZeneca and Gilead's Kite committed up to a combined USD 3.45 Bn in 2025 on in-vivo CAR-T deals, while North America keeps a 45.0% share of global sales.
The Global CAR-T Cell Therapy market reached USD 4,372.8 Mn in 2025 and is projected to hit USD 23,915.3 Mn by 2035, an 18.52% CAGR over 2026–2035, according to Vectomat Insights. North America leads with 45.0% share, autologous therapies hold 68.0% of revenue, and Asia Pacific grows fastest as China, Japan and South Korea add approved products and reimbursement.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global CAR-T Cell Therapy Market Size, Share, Growth & Forecast By Product Type, Target Antigen, Application, and End User, 2026–2035 |
| Base Year Market Size | USD 4,372.8 Mn (2025) |
| Forecast Market Size | USD 23,915.3 Mn (2035) |
| CAGR | 18.52% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (45.0%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | Autologous CAR-T (68.0%) |
| Dominant Application | Non-Hodgkin Lymphoma |
| Report Format | |
| Publisher | Vectomat Insights |
What Advanced Therapy Leaders Need to Know About the CAR-T Cell Therapy Market
Biotech R&D Heads: In-vivo CAR-T has moved from academic curiosity to a USD 3.45 Bn deal category inside six months of 2025, with AbbVie, AstraZeneca and Kite all buying platforms. If your pipeline still assumes ex vivo manufacturing for every program, you're planning against a cost curve that competitors are trying to break.
Hospital CMOs: The June 2025 REMS removal halved the post-infusion stay requirement to two weeks, and outpatient infusions already reached 35% of U.S. CAR-T administrations in 2025. Capacity plans built on inpatient beds alone will undersize the 2026 budget cycle.
Regulatory Affairs Directors: China cleared the first solid-tumor CAR-T, CARsgen's satri-cel, in June 2026, and the FDA's decision on anito-cel lands on 23 December 2026. Sponsors without a parallel China or Korea filing strategy are leaving their fastest-growing geography to local rivals.
Healthcare Investors: Gilead paid a 79% premium for Arcellx and booked USD 7.0 Bn of acquired IPR&D, a signal that BCMA assets with clean safety data command scarcity pricing. With Kymriah sales down 14% in 2025, CD19 incumbency is no longer a moat.
Payer and Market Access Executives: U.S. list prices now sit between roughly USD 462,000 and USD 594,000 per infusion and rose 3-7% a year between 2022 and 2025. Outcomes-based contracts, such as Carvykti's 2026 pay-for-performance listing in Australia, are the template payers should expect to negotiate this year.
What Is the CAR-T Cell Therapy Market?
CAR-T Cell Therapy Market refers to the commercial sale of chimeric antigen receptor T-cell therapies, in which a patient's or a donor's T cells are engineered to recognize a tumor antigen and then infused as a living drug. Why now? In June 2025 the FDA scrapped the REMS programs for all six autologous products on the U.S. market, cutting the required stay near a treatment center to two weeks. That one decision widens the pool of hospitals able to infuse. Big pharma has noticed: Gilead paid USD 7.8 Bn for Arcellx in 2026. Vectomat Insights sizes the market at USD 4,372.8 Mn in 2025, heading to USD 23,915.3 Mn by 2035.
How Is the CAR-T Cell Therapy Market Segmented?
Autologous CAR-T accounts for 68.0% of 2025 revenue, or USD 2,973.5 Mn, because every therapy approved by the FDA so far is built from the patient's own T cells. Allogeneic CAR-T edges ahead on growth, compounding at 18.5% a year between 2023 and 2025, and it's where the next clinical readouts sit: Allogene's cema-cel cleared an interim futility check in April 2026 with 10 of 12 treated patients managed as outpatients. By antigen, CD19-targeted products hold 50.0% share, while BCMA-targeted therapies for myeloma take 28.0%.
This report segments the CAR-T Cell Therapy market as follows:
- By Product Type: Autologous CAR-T, Allogeneic CAR-T, In-Vivo CAR-T
- By Target Antigen: CD19-Targeted, BCMA-Targeted, CD22-Targeted, Others
- By Application: Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Solid Tumors, Others
- By End User: Hospitals & Cancer Centers, Specialty Treatment Centers, Academic & Research Institutes
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa
Which Region Leads the CAR-T Cell Therapy Market?
North America controls 45.0% of global CAR-T revenue, worth USD 1,967.8 Mn in 2025, and the United States accounts for USD 1,574.2 Mn of it thanks to seven approved products and roughly 250 accredited treatment centers. Europe follows with 27.0%, anchored by Germany at USD 354.2 Mn. Asia Pacific, at 19.0%, is the fastest-growing region: South Korea approved its first home-grown CAR-T in April 2026 and China now has nine approved products. Latin America takes 4.0%, the Middle East 3.0% and Africa 2.0%, where access is still built around academic programs and licensing deals.
What Is Driving the CAR-T Cell Therapy Market?
Earlier-Line and New-Indication Label Expansion — Breyanzi sales jumped 82% to USD 1,358 Mn in 2025 as CAR-T moved up the treatment sequence, and the FDA added marginal zone lymphoma to its label in December 2025.
Regulatory Easing and Outpatient Delivery — The FDA's June 2025 decision to scrap REMS rules for six CAR-Ts cut the required stay near a treatment center to two weeks, opening the door to community and outpatient infusion.
Big-Pharma Investment in Next-Generation Platforms — Gilead closed a USD 7.8 Bn acquisition of Arcellx in April 2026, capping a run of deals that put up to USD 3.45 Bn into in-vivo CAR-T in 2025 alone.
Anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy.
(Source: Gilead Sciences announcement of the Arcellx acquisition (via Financier Worldwide), 2026-02-23)
What Is Restraining the CAR-T Cell Therapy Market?
High Treatment Cost and Reimbursement Gaps — U.S. list prices run from about USD 462,000 to USD 594,000 per infusion, and only around 20% of eligible U.S. patients receive CAR-T today.
Manufacturing Lead Times and Treatment-Center Access — A median 14-day manufacturing turnaround and a limited network of accredited centers still leave many eligible patients untreated, especially outside major cities.
Even with these headwinds, the market is on track to grow from USD 4,372.8 Mn in 2025 to USD 23,915.3 Mn by 2035.
What Industry Leaders Are Saying About the CAR-T Cell Therapy Market
Historically, CAR T has largely been out of reach for community practices.
(Source: Targeted Oncology, 2026-04)
Commercial CAR-T products are economically unfeasible for Brazil's public health system, which is why the goal is a completely national technology that SUS patients can access. (paraphrased)
(Source: Jornal da USP, 2025-01)
Eliminating the REMS that is no longer needed also expedites the delivery of potentially curative treatments.
(Source: Managed Healthcare Executive, 2025-06-27)
The potential to dramatically expand CAR-T cell therapy access for patients.
(Source: Caribou Biosciences press release (SEC Form 8-K exhibit), 2026-08-13)
Many more patients now stand to benefit from this CAR-T cell therapy on the NHS.
(Source: NICE news release, 2026-01)
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Product Type |
|
| By Target Antigen |
|
| By Application |
|
| By End User |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the CAR-T Cell Therapy Market?
Key players operating in the Global CAR-T Cell Therapy market include Gilead Sciences (U.S.), Novartis (Switzerland), Bristol Myers Squibb (U.S.), Johnson & Johnson (U.S.), Legend Biotech (U.S.), Autolus Therapeutics (U.K.), JW Therapeutics (China), CARsgen Therapeutics (China), IASO Biotherapeutics (China), Allogene Therapeutics (U.S.), Caribou Biosciences (U.S.), AbbVie (U.S.), AstraZeneca (U.K.), ImmunoACT (India), and Miltenyi Biomedicine (Germany), among others. Five product owners still collect most of the revenue. But the deal flow tells you where they're headed: Gilead's USD 7.8 Bn Arcellx buyout and three in-vivo acquisitions in 2025 show incumbents paying up for the next platform rather than defending the current one.
What Recent Developments Are Shaping the CAR-T Cell Therapy Market?
March 2025 — AstraZeneca: Agreed to acquire Belgium's EsoBiotec and its ENaBL in-vivo lentiviral platform for up to USD 1.0 Bn (USD 425 Mn upfront).
June 2025 — U.S. Food and Drug Administration: Eliminated REMS programs for six autologous CD19 and BCMA CAR-T therapies, cutting the required stay near the treatment center to two weeks.
June 2025 — AbbVie: Announced the acquisition of Capstan Therapeutics, developer of in-vivo LNP-mRNA CD19 CAR-T candidate CPTX2309 for autoimmune disease, for up to USD 2.1 Bn.
December 2025 — Bristol Myers Squibb: Received FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma after two or more prior lines, the first CAR-T approved in that disease.
April 2026 — Gilead Sciences: Completed its acquisition of Arcellx for about USD 7.8 Bn, adding BCMA CAR-T anito-cel ahead of an FDA decision expected by 23 December 2026.
June 2026 — CARsgen Therapeutics: China's NMPA approved satri-cel, a Claudin18.2-targeted CAR-T for advanced gastric or gastroesophageal junction cancer, the world's first solid-tumor CAR-T approval.
Frequently Asked Questions
What is the CAR-T Cell Therapy market size and forecast?
The Global CAR-T Cell Therapy market was valued at USD 4,372.8 Mn in 2025 and is projected to reach USD 23,915.3 Mn by 2035, a CAGR of 18.52% over 2026–2035. Growth comes from earlier-line approvals in lymphoma and myeloma, the FDA's 2025 removal of REMS rules, and new allogeneic and in-vivo platforms that promise lower cost and faster treatment, according to the Vectomat Insights CAR-T Cell Therapy Market report.
Which region dominates the CAR-T Cell Therapy market?
North America dominates with a 45.0% share of 2025 revenue, worth USD 1,967.8 Mn, and the United States alone accounts for USD 1,574.2 Mn. Seven FDA-approved products and about 250 accredited treatment centers give the U.S. its lead. Europe follows at 27.0%, while Asia Pacific is the fastest-growing region as China, Japan and South Korea add approvals and reimbursement, per Vectomat Insights analysis.
What are the key growth drivers of the CAR-T Cell Therapy market?
Three forces drive the market. Labels are moving into earlier treatment lines, lifting sales of products such as Breyanzi, which grew 82% in 2025. Regulators are easing delivery rules, led by the FDA's June 2025 REMS removal. And large pharma groups are funding next-generation platforms, from AbbVie's Capstan deal to Gilead's USD 7.8 Bn Arcellx acquisition, according to the Vectomat Insights CAR-T Cell Therapy Market report.
Who are the leading companies in the CAR-T Cell Therapy market?
Leading companies include Gilead Sciences, Novartis, Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Autolus Therapeutics, JW Therapeutics, CARsgen Therapeutics, IASO Biotherapeutics, Allogene Therapeutics, Caribou Biosciences, AbbVie, AstraZeneca, ImmunoACT and Miltenyi Biomedicine. Five product owners earn most revenue today, but deal activity is shifting toward in-vivo and BCMA assets. Johnson & Johnson and Legend Biotech's Carvykti is the fastest-growing approved product, with Q2 2026 sales up about 50%, according to Vectomat Insights.
How is the CAR-T Cell Therapy market segmented?
The market is segmented by Product Type (Autologous, Allogeneic and In-Vivo CAR-T), Target Antigen (CD19, BCMA, CD22 and Others), Application (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Solid Tumors and Others) and End User (Hospitals & Cancer Centers, Specialty Treatment Centers, Academic & Research Institutes). Autologous CAR-T leads with 68.0% share, per the Vectomat Insights CAR-T Cell Therapy Market report.
How can I access the full VMI CAR-T Cell Therapy market report?
The full report runs to 300+ pages with 96 tables and 72 figures, covering sub-segment revenue for 2023–2025, forecasts to 2035, 35+ country analyses and profiles of 15 companies. You can request a free sample or buy the complete report at www.vectomatinsights.com, or email sales@vectomatinsights.com for licensing and customization options. Delivery is in PDF format by email and through the online portal, from Vectomat Insights.
Access the Complete CAR-T Cell Therapy Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is a leading market research company. We create authoritative, data-forward reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organisations but also with the newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is updated constantly in order to fulfil our clients' requirements for prompt and direct online access. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312